Edwards Lifesciences Corp EW reported Q3 adjusted EPS of $0.61, up 13% Y/Y, missing the Wall Street consensus of $0.62.
The company saw persistent U.S. hospital staffing shortages and COVID headwinds in Japan affect its TAVR sales.
Edwards’ TAVR sales only grew 1% Y/Y in Q3, reaching $862 million. In the U.S., Edwards’ TAVR procedures increased in the mid-single digits versus the prior year.
Q3 sales reached $1.32 billion, up 1% (+7% on constant currency), slightly below the consensus of $1.33.
Edwards Lifesciences regulatory wins during Q3 included FDA approval and the CE Mark of its Pascal Precision system for patients with degenerative mitral regurgitation (DMR).
Guidance: Edwards Lifesciences suspect that U.S. hospital staffing challenges and a strong U.S. dollar will persist.
The company revised FY22 sales guidance at the low end of the company’s previous range of $5.35-$5.55 billion, compared to the consensus of $5.47 billion.
It projects an FY22 adjusted EPS of $2.40-$2.50, down from the previous range of $2.50-$2.65 and the consensus of $2.51.
For Q4, Edwards expects reported sales and adjusted EPS to be similar to the third quarter.
Price Action: EW shares are down 15.9% at $72.57 on the last check Friday.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok
